Why is this ASX All Ords biotech share crashing 12% today?

This biotech is having a day to forget on Tuesday…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price is having a difficult day.

In afternoon trade, the biotechnology company's shares are down 12% to $1.48.

This makes the Paradigm share price one of the worst performers on the All Ordinaries index today.

A health professional wearing a stethoscope and scrubs shrugs with uncertainty.

Image source: Getty Images

Why is the Paradigm share price sinking?

Investors have been hitting the sell button on Tuesday after Paradigm announced the surprise exit of its CEO and managing director, Marco Polizzi.

According to the release, Mr Polizzi has stepped down from his role immediately and will cease employment with the company on 20 February.

Paradigm only announced the appointment of Polizzi at the end of May, with the experienced pharmaceutical industry executive commencing in the role on 1 July. At the time, the company hyped up his appointment, describing him as "a CEO with the skills to fully unlock the commercial value of the company."

No reason was given for the CEO's exit after just a few months with the company. Nor did Polizzi leave a parting comment, which is never a good look and could potentially be an indication of boardroom tensions.

What now?

The Paradigm board has acted quickly and appointed the company's founder and non-executive chairman Paul Rennie as its new leader. He said:

I am pleased to advise that the personal circumstances that originally required my stepping down from the Managing Director role in 2021, have now been successfully resolved. I look forward to working closely again with the Paradigm executive team and the Board in continuing our journey together.

Following today's decline, the Paradigm share price has now lost almost a third of its value over the last 12 months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

Are investors taking a big gamble chasing 4DX shares higher and higher?

Investor interest in this ASX healthcare tech stock is booming.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »